Brotman Melissa A, Kircanski Katharina
Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.
Emotion and Development Branch, National Institute of Mental Health, Bethesda, Maryland.
J Am Acad Child Adolesc Psychiatry. 2023 Mar;62(3):292-293. doi: 10.1016/j.jaac.2022.07.009. Epub 2022 Jul 30.
Research on the assessment, diagnosis, and treatment of clinically impairing irritability in children and adolescents has increased dramatically over the past several decades. Increased attention can be traced to controversy arising in the 1990s regarding the nosological status of youth with severe nonepisodic irritability (for a review, see). Growing out of this work, disruptive mood dysregulation disorder was introduced in DSM-5. Critically, in recent years, irritability has been conceptualized as a symptom or feature manifesting transdiagnostically across numerous mood, anxiety, disruptive behavior, and neurodevelopmental disorders. The comprehensive and timely meta-analysis by Breaux et al. in the current issue of the Journal reviews pharmacological and nonpharmacological interventions for this transdiagnostic conceptualization of irritability.
在过去几十年里，关于儿童和青少年临床损害性易激惹的评估、诊断和治疗的研究急剧增加。关注度的提高可追溯到20世纪90年代出现的关于严重非发作性易激惹青少年的疾病分类地位的争议（有关综述，见）。基于这项工作，《精神疾病诊断与统计手册》第5版引入了破坏性心境失调障碍。至关重要的是，近年来，易激惹已被概念化为一种症状或特征，在多种情绪、焦虑、破坏性行为和神经发育障碍中跨诊断地表现出来。Breaux等人在本期杂志上进行的全面而及时的荟萃分析回顾了针对这种易激惹跨诊断概念化的药物和非药物干预措施。
